A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Recruiting in Palo Alto (17 mi)

+11 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Elevar Therapeutics

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing rivoceranib, a medication, in adults whose ACC cancer has come back or spread. Rivoceranib aims to block signals that help cancer cells grow. Participants will stay on the treatment as long as it is effective and tolerable.

Eligibility Criteria

Inclusion Criteria

Your organs and bone marrow must be working well enough within 14 days before starting the study drug rivoceranib.

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Male and female participants of reproductive potential who agree to use both a highly effective method of birth control (for example, implants, injectables, combined oral contraceptives, some intrauterine devices, complete abstinence, or sterilized partner) and a barrier method (for example condoms, cervical ring, sponge, etc.) during the period of therapy and for 30 days after the final dose of rivoceranib.

See 6 more

Exclusion Criteria

Prior chemotherapy, radiation therapy or major surgery within 4 weeks prior to rivoceranib administration or presence of any nonhealing wound (procedures such as catheter placement are not considered to be major surgery). Prior immunotherapy within 12 weeks prior to first dose of study drug. Palliative radiotherapy to non-target lesions within 2 weeks prior to rivoceranib administration or biopsy any time prior to rivoceranib administration is permitted.

Participants who have not recovered to ≤Grade 1 from prior tyrosine kinase inhibitor-related adverse events

You are allergic to rivoceranib or any of the ingredients in it.

See 21 more